Qingxiang Lin
Qingxiang Lin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Robert M. Straubinger
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA
41 shared publications - Wen Wee Ma
Department of Hematology Oncology Cleveland Clinic Cleveland Ohio USA
40 shared publications - Christopher J. Scott
The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7AE, United Kingdom
39 shared publications - Ewa K. Stachowiak
Department of Pathology and Anatomical Sciences, University at Buffalo, State University of New York, Buffalo, New York
39 shared publications - Gerard P. Quinn
The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
39 shared publications - Joseph A. Spernyak
Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, USA
39 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S1. Cell line information and responses to MRTX1133 for 72h.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S1. Cell line information and responses to MRTX1133 for 72h.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S3. Effect of MAPK reactivation over 0-96h exposure of MRTX1133 on KRASG12D-mutant PDAC cell lines.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S3. Effect of MAPK reactivation over 0-96h exposure of MRTX1133 on KRASG12D-mutant PDAC cell lines.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S1. Effect of KRASG12D inhibition on cancer cell lines.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S1. Effect of KRASG12D inhibition on cancer cell lines.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Purpose:Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common. Mutant-selective KRASG12D inhibitors (KRASiG12D) have demonstrated promising initial clinical activity in KRASG12D-mutant PDAC. However, adaptive resistance to KRASi constrains efficacy in some tumor types, such as colorectal cancer, in which EGFR-mediated RAS–MAPK pathway reactivation can be targeted to improve response. Some studies have suggested a similar role for EGFR in PDAC, but the mechanisms of adaptive resistance to KRAS inhibition are unclear.Experimental Design:Mechanisms of adaptive resistance to KRASiG12D were investigated in a panel of KRASG12D-mutant PDAC models.Results:We observed receptor tyrosine kinase (RTK)–driven adaptive reactivation of RAS pathway signaling following KRASiG12D in PDAC models. EGFR was a primary driver of adaptive RAS–MAPK reactivation in some models but was limited to those with epithelial differentiation. Conversely, adaptive RAS–MAPK reactivation in models with mesenchymal differentiation was primarily driven by FGFR signaling. In clinical PDAC specimens from The Cancer Genome Atlas, EGFR and ERBB3 expression was highly correlated with the expression of epithelial markers, whereas the expression of FGFR1 and mesenchymal markers was correlated. Notably, a RAS(ON) multi-selective inhibitor, which inhibits both wild-type and mutant RAS, abrogated RAS–MAPK reactivation in combination with KRASi in both epithelial and mesenchymal models and led to more consistent antitumor activity compared with combinations of KRASi and EGFR blockade.Conclusions:In PDAC, adaptive RAS–MAPK reactivation following KRASG12D inhibition can be mediated by different RTKs and influenced by cell state. Combinations of mutant-selective KRASi and RAS(ON) multi-selective inhibitors may represent a promising universal strategy to surmount adaptive resistance in patients with PDAC.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Purpose:Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common. Mutant-selective KRASG12D inhibitors (KRASiG12D) have demonstrated promising initial clinical activity in KRASG12D-mutant PDAC. However, adaptive resistance to KRASi constrains efficacy in some tumor types, such as colorectal cancer, in which EGFR-mediated RAS–MAPK pathway reactivation can be targeted to improve response. Some studies have suggested a similar role for EGFR in PDAC, but the mechanisms of adaptive resistance to KRAS inhibition are unclear.Experimental Design:Mechanisms of adaptive resistance to KRASiG12D were investigated in a panel of KRASG12D-mutant PDAC models.Results:We observed receptor tyrosine kinase (RTK)–driven adaptive reactivation of RAS pathway signaling following KRASiG12D in PDAC models. EGFR was a primary driver of adaptive RAS–MAPK reactivation in some models but was limited to those with epithelial differentiation. Conversely, adaptive RAS–MAPK reactivation in models with mesenchymal differentiation was primarily driven by FGFR signaling. In clinical PDAC specimens from The Cancer Genome Atlas, EGFR and ERBB3 expression was highly correlated with the expression of epithelial markers, whereas the expression of FGFR1 and mesenchymal markers was correlated. Notably, a RAS(ON) multi-selective inhibitor, which inhibits both wild-type and mutant RAS, abrogated RAS–MAPK reactivation in combination with KRASi in both epithelial and mesenchymal models and led to more consistent antitumor activity compared with combinations of KRASi and EGFR blockade.Conclusions:In PDAC, adaptive RAS–MAPK reactivation following KRASG12D inhibition can be mediated by different RTKs and influenced by cell state. Combinations of mutant-selective KRASi and RAS(ON) multi-selective inhibitors may represent a promising universal strategy to surmount adaptive resistance in patients with PDAC.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S8. Combination effects of KRASi+EGFRi vs. KRASi+FGFRi.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S8. Combination effects of KRASi+EGFRi vs. KRASi+FGFRi.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S6. Statistical comparison of median survival for KP-4 model.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S6. Statistical comparison of median survival for KP-4 model.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S5. Raw data used in Figure 5, colony area (% of control)
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S5. Raw data used in Figure 5, colony area (% of control)
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S9. Western blot analysis of combined MRTX1133+RMC-7977 in epithelial lines SU86.86 and HPAF-II.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S9. Western blot analysis of combined MRTX1133+RMC-7977 in epithelial lines SU86.86 and HPAF-II.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S7. Statistical comparison of median survival for SW1990 model.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Table S7. Statistical comparison of median survival for SW1990 model.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S10. Effects of co-inhibition of KRAS and wild-type RAS in KRASmutant PDAC tumor models.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
Supplementary Figure S10. Effects of co-inhibition of KRAS and wild-type RAS in KRASmutant PDAC tumor models.